Organised by SHC
For 2025 ONLY:
Asian HBV/HDV Endpoints Consensus Meeting
For Scientists, Clinician Scientists and
Pharmacists and Industry Experts
22 to 24 August 2025
8:30 am to 5:00 pm (SGT)
Asian HBV/HDV Endpoints Consensus Meeting
REGISTRATION FOR The 1st Asian Hepatology Summit includes Asian HBV/HDV Endpoints Consensus Meeting.
HBV Cure is now becoming a reality with new drugs being tested in phase 3 clinical trials to achieve HBV Cure. This will bring hope to 257 Million Chronic Hepatitis B patients globally but exactly what is Hepatitis B Cure? Patients, doctors, scientists and pharmaceutical companies need to understand the disease, the new treatments and reach consensus on Hepatitis B Cure. HDV is emerging as an important disease for which therapy is rapidly evolving
This will be a three (3) day meeting focusing on establishing consensus as well as examining challenges and opportunities in Hepatitis B and Hepatitis D endpoints, from the clinical, scientific and public health perspectives in Asia.
• The Objectives are:
> Endpoints standardization and consensus-building.
> Novel treatments likely to achieve HBV Cure.
> Blood and liver biomarkers for HBV Cure.
> Definitions and Treatments for HDV Cure.
Who Should Attend?
Asian HBV/HDV Endpoints Consensus Meeting is designed for Clinicians, Scientists (virologists, Immunologists), Pharma Executives and Industry Experts.
REGISTER HERE for The 1st Asian Hepatology Summit which includes Asian HBV/HDV Endpoints Consensus Meeting
To access SHC e-Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)
Meet Our Experts
Coming Soon..
REGISTER HERE for The 1st Asian Hepatology Summit which includes Asian HBV/HDV Endpoints Consensus Meeting
To access SHC e-Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)
Call for Abstracts
Submission Deadline: 27 June 2025
We invite all interested parties to present their research papers. Click on below Abstracts and Posters for further information.
Abstracts will be reviewed by the Abstract Selection Committee and accepted submissions will be posted on Abstract & Poster Gallery in our website and in the Poster Hall.
Asian HBV/HDV Endpoints Consensus Meeting Scientific Draft Preliminary Programme.
August, 2025
22
| Programme | Time (SGT) |
|---|---|
| Session 1: Overview |
|
| a. Opening lecture: A need for Asian Consensus HBV Endpoint meeting | 8.30 – 8.45 |
| b. Scope of the meeting and agenda items | 8.45 – 9.00 |
| c. Overview of HBV virology leading to HBsAg loss | 9.00 – 9.15 |
| d. Overview of HBV immunology leading to functional cure | 9.15 – 9.30 |
| e. Discussion | 9.30 – 9.50 |
| Tea Break | 9.50 – 10.10 |
| Session 2 Consensus Statement 1: Consensus On Cure Definitions Revisiting terminology for HBV endpoints for patients and clinical trials of treatments of CHB: partial cure, functional cure, occult HBV infection, virological cure and complete cure |
|
| a. HCC risk and HBV DNA vs HBsAg Levels | 10.10 – 10.30 |
| b. HBsAg sero-reversion and HBV relapse after functional cure | 10.30 – 10.50 |
| c. Overview of the HBV cure landscape | 10.50 – 11.10 |
| Debate: Partial cure is an acceptable endpoint of HBV therapy For: Against: |
11.10 – 11.40 |
| d. Definitions and outcomes of Occult HBV infection | 11.40 – 12.00 |
| e. From functional cure to virological cure | 12.00 – 12.20 |
| f. Discussion | 12.20 – 12.40 |
| Lunch Symposium | 12.40 – 14.10 |
| Session 3: Consensus Statement 2: Biomarkers In Clinical Studies Of CHB |
|
| (1) Novel biomarkers in clinical trials and clinical practice | |
| a. Spectrum of HBV biomarkers and virological pathways | 14.10 – 14.30 |
| b. Utility of novel biomarkers in natural history of CHB | 14.30 – 14.50 |
| c. Utility of novel biomarkers during treatment | 14.50 – 15.10 |
| d. Discussion | 15.10 – 15.30 |
| Tea Break | 15.30 – 15.45 |
| (2) The role of evaluating the liver microenvironment in clinical trials of CHB | |
| a. What to measure in the liver microenvironment | 15.45 – 16.05 |
| b. HBV integration and its loss during functional cure | 16.05 – 16.25 |
| c. FNA vs LBx and the utiliy of liver tissue in clinical trials | 16.25 – 16.45 |
| d. Discussion | 16.45 – 17.15 |
August, 2025
23
| Programme | Time (SGT) |
|---|---|
| Session 4: Consensus Statement 3: The Role Of Existing Treatment Strategies In Functional Cure Existing treatment strategies including strategies for HBV cure |
|
| a. Oral antiviral therapy and new HBV guidelines | 8.30 – 8.50 |
| b. Long term outcomes of NUC therapy | 8.50 – 9.10 |
| c. The use of Peginterferon in Asia | 9.10 – 9.30 |
| d. Stopping NUC therapy | 9.30 – 9.50 |
| e. Discussion | 9.50 – 10.10 |
| Tea Break | 10.10 – 10.30 |
| Session 5: Consensus Statement 4: Novel Therapies For Functional Cure Novel therapeutics leading to functional cure – controversies |
|
| a. ASO RNA therapeutics state of the art | 10.30 – 10.50 |
| b. siRNA combination therapy | 10.50 – 11.10 |
| c. Monoclonal Ab | 11.10 – 11.30 |
| d. Immunotherapy current prospects for functional cure | 11.30 – 11.50 |
| e. Gene therapy and prospects for HBV complete cure | 11.50 – 12.10 |
| f. Discussion | 12.10 – 12.45 |
| Lunch Symposium | 12.45 – 14.15 |
| Session 6: Consensus Statement 5: Diagnosis And Management Of ALT Flares ALT flares |
|
| a. Definitions of ALT flares and natural history and prediction of ACLF | 14.15 – 14.35 |
| b. ALT flares associated with novel therapies: risks and benefits | 14.35 – 14.55 |
| c. Management of ALT flares, beyond antiviral therapy pros and cons | 14.55 – 15.15 |
| d. Discussion | 15.15 – 15.35 |
| Close of Day 2 | |
August, 2025
24
| Programme | Time (SGT) |
|---|---|
| Session 7: Delta Hepatitis: Consensus Statement 6: |
|
| (1) The burden of HDV in Asia and endpoints of Delta cure | |
| a. Overview of delta virology & immunology | 8.40 – 9.00 |
| b. Asian epidemiology and natural history, | 9.00 – 9.20 |
| (2) Delta Hepatitis endpoints | |
| a. HBV and HDV biomarkers for delta management | 9.20 – 9.40 |
| b. Staging liver disease by Non invasive tests (NIT): pros and cons | 9.40 – 10.00 |
| c. What is the appropriate endpoints for Delta cure | 10.00 – 10.20 |
| d. Discussion | 10.20 – 10.40 |
| Tea Break | 10.40 – 11.00 |
| Session 8: Consensus Statement 7: Management Of HDV In Asia Delta Hepatitis existing and emerging therapy |
|
| a. Any role for pegIFN monotherapy in 2025? | 11.00 – 11.20 |
| b. Bulevirtide (BLV) monotherapy or in combination | 11.20 – 11.40 |
| c. New anti HDV therapeutics: phase 2 clinical studies | 11.40 – 12.00 |
| d. Discussion | 12.00 – 12.15 |
| Lunch Break | 12.15 – 13.30 |
| Session 9: Consensus Statement Session |
|
| a. Discussions | 13.30 – 15.30 |
| Tea Break | 15.30 – 15.45 |
| Session 10: HBV/HDV Elimination Forum |
|
| How is the current status of HBV elimination globally | 15.45 – 16.00 |
| What are the challenges to HBV elimination in Asia | 16.00 – 16.15 |
| What practical steps can we take to achieve WHO 2030 goals | 16.15 – 16.30 |
| What is the status, challenges and solutions for HDV elimination in Asia | 16.30 – 16.45 |
| What roles can patients take in HBV Elimination | 16.45 – 17.00 |
| How can NGOs support the mission of HBV/HDV elimination | 17.00 – 17.15 |
| Close of Day 3 and Conference | 17.15 – 17.20 |